
Commentary|Podcasts|May 23, 2022
Pharmacy Focus: Oncology Edition - PARP Inhibitors in Ovarian Cancer
Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.
Advertisement
In the second episode of Pharmacy Focus: Oncology Edition, Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5